Revance Therapeutics (RVNC) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow

DAXI AESTHETICS - The global facial aesthetics neuromodulator opportunity is approximately $2.2 billion[21] - Over 7 million neuromodulator procedures are performed annually in the U S[21] - In SAKURA 1, 73 6% of subjects achieved ≥ 2-point composite response vs 0% with placebo[27] - In SAKURA 2, 74 0% of subjects achieved ≥ 2-point composite response vs 1% with placebo[27] NEUROMODULATOR MARKET - The global neuromodulator market is currently valued at $5 1 billion[15] - Facial aesthetics account for 44% of the global neuromodulator market[15] - Therapeutics account for 56% of the global neuromodulator market[17] - The global neuromodulator market is projected to reach $9 7 billion by 2027[16] TEOXANE Partnership - Revance has an exclusive U S distribution agreement for TEOXANE's RHA dermal fillers[47] - The U S filler market is valued at $1 1 billion[47] - The U S HA filler market is growing at a CAGR of 10% and is projected to reach $2 1 billion in sales by 2025[51] DAXI THERAPEUTICS - The global market opportunity for therapeutic indications of botulinum toxin is $2 5 billion[38]